COMMUNIQUÉS West-GlobeNewswire

Abalos Therapeutics Publishes Two Articles in Viruses Further Validating its AdaptInnate Approach to Treat Solid Tumors
16/09/2026
Preclinical findings further strengthen the scientific foundation for Abalos’ AdaptInnate approach, which leverages systemically administered non-lytic arenaviruses to selectively target solid tumors by triggering body- [...]
Kailera Therapeutics to Participate in September Investor Conferences
16/09/2026
WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/09/2026
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases [...]
AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026
16/09/2026
MILAN, Sept. 16, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV [...]
Shock Top and Spirit Halloween Brew Up a Scary Good Collaboration
16/09/2026
Limited-Edition Candy Corn Wheat Ale Craft Beer and Spirit Halloween-Exclusive Wedgehead Costume Bring Big Flavor, Big Fun, and Head-Turning Halloween Energy to Fans Nationwide PORTLAND, Ore., Sept. 16, 2026 (GLOBE [...]
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
16/09/2026
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
Sironax Announces Option Exercise and Asset Purchase
16/09/2026
Novartis exercises option to acquire Sironax’s brain delivery platform Sironax to advance three clinical-stage programs and multiple early-stage candidates using purchase proceeds Sironax to retain development rights to [...]
Coave Therapeutics Strengthens Leadership Team to Advance Lead Gene Therapy Program into the Clinic
16/09/2026
Senior appointments add world-class expertise across gene therapy development, ophthalmology, CMC, regulatory affairs and global operations to support the next phase of growth Carl De Luca, PhD, appointed Chief [...]
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
16/09/2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
16/09/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: [...]
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
16/09/2026
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and [...]
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
16/09/2026
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ® Combining ART27.13 with semaglutide [...]
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
16/09/2026
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice [...]
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
16/09/2026
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced [...]
ESA Letter in Utah: RealESALetter.com Gains Recognition Among Utah Residents
16/09/2026
SALT LAKE CITY, UT, Sept. 16, 2026 (GLOBE NEWSWIRE) -- RealESALetter.com connects Utah residents with licensed mental health professionals for individualized emotional support animal (ESA) evaluations and documentation [...]
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
16/09/2026
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and [...]
MESSAGE DU CEO DE TME PHARMA
16/09/2026
MESSAGE DU CEO DE TME PHARMA Berlin, Allemagne, le 16 septembre 2026, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans le développement de [...]
TME PHARMA CEO MESSAGE
16/09/2026
TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for [...]
First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
16/09/2026
September 16, 2026 News Release First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“ [...]

Pages